544 related articles for article (PubMed ID: 32213091)
1. A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer.
Green AK; Feinberg J; Makker V
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-7. PubMed ID: 32213091
[TBL] [Abstract][Full Text] [Related]
2. Optimizing immunotherapy for gynecologic cancers.
Rubinstein MM; Makker V
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):1-8. PubMed ID: 31833942
[TBL] [Abstract][Full Text] [Related]
3. Biomarker-driven therapy in endometrial cancer.
Karpel H; Slomovitz B; Coleman RL; Pothuri B
Int J Gynecol Cancer; 2023 Mar; 33(3):343-350. PubMed ID: 36878569
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract][Full Text] [Related]
5. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
6. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
Hill BL; Graf RP; Shah K; Danziger N; Lin DI; Quintanilha J; Li G; Haberberger J; Ross JS; Santin AD; Slomovitz B; Elvin JA; Eskander RN
Int J Gynecol Cancer; 2023 Apr; 33(4):504-513. PubMed ID: 36750267
[TBL] [Abstract][Full Text] [Related]
7. Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.
Bartoletti M; Montico M; Lorusso D; Mazzeo R; Oaknin A; Musacchio L; Scambia G; Puglisi F; Pignata S
Cancer Treat Rev; 2024 Apr; 125():102701. PubMed ID: 38422895
[TBL] [Abstract][Full Text] [Related]
8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
9. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C III; Guo W; Im E; Zildjian S; Han X; Duan T; Veneris J; Pothuri B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064011
[TBL] [Abstract][Full Text] [Related]
10. How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.
Maiorano BA; Maiorano MFP; Cormio G; Maglione A; Lorusso D; Maiello E
Front Oncol; 2022; 12():844801. PubMed ID: 35494078
[TBL] [Abstract][Full Text] [Related]
11. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer.
Kasherman L; Ahrari S; Lheureux S
Future Oncol; 2021 Mar; 17(8):877-892. PubMed ID: 33251877
[TBL] [Abstract][Full Text] [Related]
12. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
Gargiulo P; Della Pepa C; Berardi S; Califano D; Scala S; Buonaguro L; Ciliberto G; Brauchli P; Pignata S
Cancer Treat Rev; 2016 Jul; 48():61-8. PubMed ID: 27362548
[TBL] [Abstract][Full Text] [Related]
13. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy.
Morse MA; Hochster H; Benson A
Oncologist; 2020 Jan; 25(1):33-45. PubMed ID: 31383813
[TBL] [Abstract][Full Text] [Related]
15. Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors.
Sobecki-Rausch J; Barroilhet L
Curr Treat Options Oncol; 2019 Nov; 20(11):83. PubMed ID: 31754884
[TBL] [Abstract][Full Text] [Related]
16. Advanced and recurrent endometrial cancer: State of the art and future perspectives.
Tronconi F; Nero C; Giudice E; Salutari V; Musacchio L; Ricci C; Carbone MV; Ghizzoni V; Perri MT; Camarda F; Gentile M; Berardi R; Scambia G; Lorusso D
Crit Rev Oncol Hematol; 2022 Dec; 180():103851. PubMed ID: 36257537
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer.
Hong JH; Cho HW; Ouh YT; Lee JK; Chun Y
J Gynecol Oncol; 2023 Mar; 34(2):e18. PubMed ID: 36509464
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors in endometrial cancer.
Gómez-Raposo C; Merino Salvador M; Aguayo Zamora C; García de Santiago B; Casado Sáenz E
Crit Rev Oncol Hematol; 2021 May; 161():103306. PubMed ID: 33839243
[TBL] [Abstract][Full Text] [Related]
19. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
[TBL] [Abstract][Full Text] [Related]
20. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]